|
Press Releases |
|
|
|
Monday, May 18, 2015 |
|
上海醫藥與京東宣佈開啟戰略、資本、業務等層面的全面戰略合作 |
中國醫藥產品製造及分銷市場領先的一體化醫藥公司 - 上海醫藥集團股份有限公司(「上海醫藥」或「公司」,連同其附屬公司「集團」,股份代號:601607.SH;2607.HK)5月17日晚發佈公告稱,公司與北京京東世紀貿易有限公司(「京東」)簽訂戰略合作框架協議。 more info >> |
|
Shanghai Pharmaceuticals and Jingdong Announced Comprehensive Strategic Cooperation in Strategies, Capital and Businesses |
Shanghai Pharmaceuticals Holding Co. Ltd., ("Shanghai Pharmaceuticals" or the "Company" and, together with its subsidiaries, the "Group"; stock code: 601607.SH; 02607.HK), announced on 17 May that the Company has entered into a strategic cooperative framework agreement with Beijing Jingdong Century Trading Co., Ltd. ("Jingdong"). more info >> |
|
Tuesday, April 28, 2015 |
|
上海医药2015年一季度开局良好,营收、净利增势强劲 |
中国医药产品制造及分销市场领先的一体化医药公司- 上海医药集团股份有限公司(「上海医药」或「公司」,连同其附属公司「集团」,股份代号:601607.SH;2607.HK)发布2015年第一季度报告 more info >> |
|
上海醫藥2015年一季度開局良好,營收、淨利增勢強勁 |
中國醫藥產品製造及分銷市場領先的一體化醫藥公司 - 上海醫藥集團股份有限公司(「上海醫藥」或「公司」,連同其附屬公司「集團」,股份代號:601607.SH;2607.HK)發佈2015年第一季度報告 more info >> |
|
Shanghai Pharmaceuticals Shows Strong Momentum in Q1 Revenue and Net Profit |
Shanghai Pharmaceuticals Holding Co. Ltd., ("Shanghai Pharmaceuticals" or the "Company" and, together with its subsidiaries, the "Group"; stock code: 601607.SH; 02607.HK) more info >> |
|
Monday, April 13, 2015 |
|
上海医药商业分销线下布局进一步优化 「互联网+」业态潮立风口 |
2014年,上海医药(2607)分销业务达到销售收入820亿元(人民币.下同),按年增长20.57%;毛利率6.07%,按年升0.02个百分点。行业人士表示,在药品新一轮降价、新版GSP实施、医改不确定性影响加深、厂商渠道扁平化等环境挑战下,上海医药分销业务收入增长较快,毛利率保持平稳,应属不易。 more info >> |
|
上海醫藥商業分銷線下佈局進一步優化 「互聯網+」業態潮立風口 |
2014年,上海醫藥(2607)分銷業務達到銷售收入820億元(人民幣.下同),按年增長20.57%;毛利率6.07%,按年升0.02個百分點。行業人士表示,在藥品新一輪降價、新版GSP實施、醫改不確定性影響加深、廠商渠道扁平化等環境挑戰下,上海醫藥分銷業務收入增長較快,毛利率保持平穩,應屬不易。 more info >> |
|
Thursday, April 9, 2015 |
|
上海医药聚焦领域能力提升 过半重点产品增速显著 |
上海医药(2607)最新年报资料显示,2014年64个重点产品达到销售收入66.78亿元(人民币.下同),占工业销售比重60.15%,其中, 33个品种高于或等于艾美仕公司(IMS)同类品种的增长。 more info >> |
|
上海醫藥聚焦領域能力提升 過半重點產品增速顯著 |
上海醫藥(2607)最新年報資料顯示,2014年64個重點產品達到銷售收入66.78億元(人民幣.下同),佔工業銷售比重60.15%,其中, 33個品種高於或等於艾美仕公司(IMS)同類品種的增長。 more info >> |
|
Tuesday, March 31, 2015 |
|
上海医药研发投入持续增长 研发创新积蓄发力 |
上海医药(02607)在其2014年年报中披露了最新研发进展:抗体药物研发方面,「重组人肿瘤坏死因数受体突变体-Fc 融合蛋白注射液」获临床试验批件,正进行I期临床研究 more info >> |
|
|
|
|
|
|
|
|
Latest Press Releases |
|
TOYOTA GAZOO Racing FULLY PREPARED FOR DAKAR 2025
Nov 26, 2024 17:55 JST
|
|
|
Q2 Metals Significantly Expands the Cisco Lithium Property in James Bay, Quebec, Canada
Nov 26, 2024 16:05 HKT/SGT
|
|
|
EdgePoint Infrastructure Inks Strategic Partnership with CelcomDigi to expand connectivity in Malaysia at TowerXchange Meet Up Asia 2024
Nov 26, 2024 16:00 HKT/SGT
|
|
|
Propel Global Reports Encouraging 24.2% Growth in Revenue to RM34.3 Million in Q1 FY2025
Nov 26, 2024 15:00 HKT/SGT
|
|
|
Eisai Signs Research Collaboration Agreement with The National Center of Neurology and Psychiatry to Initiate Apolipoprotein E Genetic Testing in the "AD-DMT Registry" in Japan
Nov 26, 2024 15:50 JST
|
|
|
S&P Acknowledges Fosun's Return to the USD Bond Market
Nov 26, 2024 13:30 HKT/SGT
|
|
|
GoKardz Launches Enterprise Module to Revolutionize Digital Business Card Management Empowering Businesses with Comprehensive Digital Networking Solutions
Nov 26, 2024 13:00 HKT/SGT
|
|
|
「依拉環素臨床應用綜合評價項目」終期報告發佈
Nov 26, 2024 11:11 HKT/SGT
|
|
|
'依拉环素临床应用综合评价项目'终期报告发布
Nov 26, 2024 11:04 HKT/SGT
|
|
|
富士通、社会課題解決に向けて自治体施策の効果を最大化する「Policy Twin」技術を開発
Nov 26, 2024 11:00: JST
|
|
|
Fujitsu develops Policy Twin, a new digital twin technology to maximize effectiveness of local government policies for solving societal issues
Nov 26, 2024 10:51 JST
|
|
|
GoDaddy's Airo solution is helping Asian entrepreneurs save time
Nov 26, 2024 08:00 HKT/SGT
|
|
|
Hola Prime Sets New Industry Standard as the World's Top Transparent Prop Trading Firm
Nov 25, 2024 23:00: JST
|
|
|
Hola Prime Sets New Industry Standard as the World's Top Transparent Prop Trading Firm
Nov 25, 2024 22:00 HKT/SGT
|
|
|
Lexaria's GLP-1 Human Pilot Study #3 Completes Dosing as Scheduled
Nov 25, 2024 22:00 HKT/SGT
|
|
|
|
More News >> |
|
|
|
|
|